Possible involvement of energy metabolism in the change of cytoplasm organization induced by a protein phosphatase inhibitor, calyculin A, in root hair cells of Limnobium stoloniferum.
In root hair cells of Limnobium stoloniferum, transvacuolar strands disperse and cytoplasmic spherical bodies (CSBs) emerge upon treatment with a protein phosphatase inhibitor, calyculin A (CA), whose effects were previously shown to be canceled by simultaneous treatment of the cells with a nonselective protein kinase inhibitor, K-252a. CSB formation is also suppressed by latrunculin B (LB) or cytochalasin D, actin filament depolymerization drugs, or 2,3-butanedione monoxime, an inhibitor of myosin activity. To confirm the involvement of myosin activity in CSB formation induced by CA, we examined the effect of an inhibitor of energy metabolism, NaN3, on CSB formation in root hair cells pretreated simultaneously with CA and LB. In the presence of CA-LB, CSB formation was suppressed due to the depolymerization of actin filaments. When these drugs were removed, the actin filaments recovered and CSBs emerged even in the presence of K-252a. These results indicated that the phosphorylation level in the cells is elevated during the CA-LB treatment and that a phosphorylation level sufficient for the CSB formation was sustained even after CA removal. On the other hand, CSB formation after simultaneous treatment with CA and LB was significantly suppressed in the presence of NaN3. In such cells, actin filament bundles recovered, although their organization was random. The present and previous results suggested that myosin activity is necessary for CSB formation induced by CA, and that myosin regulated by phosphorylation-dephosphorylation is implicated in the organization of the actin cytoskeleton in root hair cells.
Yokota
E
E
Department of Life Science, Graduate School of Science, Himeji Institute of Technology, Harima Science Park City, Hyogo, Japan.
Izeki
T
T
Shimmen
T
T
D000199:Actins / Q000378:metabolism; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002227:Carbazoles / Q000494:pharmacology; D003593:Cytoplasm / Q000187:drug effects / Q000648:ultrastructure*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D031321:Hydrocharitaceae / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D026121:Indole Alkaloids; D008387:Marine Toxins; D009218:Myosins / Q000378:metabolism; D010080:Oxazoles / Q000494:pharmacology*; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors*; D018517:Plant Roots / Q000166:cytology / Q000378:metabolism; D012977:Sodium Nitrite / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology*; D053778:Thiazolidines
D000199:Actins; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002227:Carbazoles; D004791:Enzyme Inhibitors; D026121:Indole Alkaloids; D008387:Marine Toxins; D010080:Oxazoles; D013844:Thiazoles; D053778:Thiazolidines; C059041:calyculin A; C049985:staurosporine aglycone; D010749:Phosphoprotein Phosphatases; D009218:Myosins; C037068:latrunculin B; D012977:Sodium Nitrite